EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial

Amanda Timler iD, Caroline Bulsara, Max Bulsara, Alistair Vickery, Angela Jacques, Jim Codde

Australasian Journal on Ageing · 2023-12 · 42 (4) · 698-709

DOI: 10.1111/ajag.13224 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Australasian Journal on Ageing, online erschienen am 15.06.2023. Verfasst von Amanda Timler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, USA. Hauptthemen laut MEDLINE: Cannabidiol, Dementia, Cannabinoids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MGC Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Dementia affects individuals older than 65 years. Currently, residential aged care facilities (RACF) use psychotropic medications to manage behavioural and neuropsychiatric symptoms of dementia (BPSD), which are recommended for short‐term use and have substantial side effects, including increased mortality. Cannabinoid‐based medicines (CBM) have some benefits that inhibit BPSD and cause minimal adverse effects (AEs), yet limited research has been considered with this population. The study aimed to determine a tolerable CBM dose (3:2 delta‐9‐tetrahydrocannabinol:cannabidiol), and assessed its effect on BPSD, quality of life (QoL) and perceived pain.

Methods

An 18‐week randomised, double‐blinded, crossover trial was conducted. Four surveys, collected on seven occasions, were used to measure changes in BPSD, QoL and pain. Qualitative data helped to understand attitudes towards CBM. General linear mixed models were used in the analysis, and the qualitative data were synthesised.

Results

Twenty‐one participants (77% female participants, mean age 85) took part in the trial. No significant differences were seen between the placebo and CBM for behaviour, QOL or pain, except a decrease in agitation at the end of treatment in favour of CBM. The qualitative findings suggested improved relaxation and sleep among some individuals. Post hoc estimates on the data collected suggested that 50 cases would draw stronger conclusions on the Neuropsychiatric Inventory.

Conclusions

The study design was robust, rigorous and informed by RACF. The medication appeared safe, with minimal AEs experienced with CBM. Further studies incorporating larger samples when considering CBM would allow researchers to investigate the sensitivity of detecting BPSD changes within the complexity of the disease and concomitant with medications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDementiaCannabinoidsAgedHumansFemaleAged, 80 and overMaleDronabinolQuality of LifeCross-Over StudiesPain

Stichwörter der Autor:innen

cannabinoidcrossover trialdementiapain, quality of life

Substanzen

CannabidiolDronabinolCannabinoids

Autor:innen und Institutionen

  • Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, USA.
  • Emerald Clinics, Fremantle, WA, USA.

ORCID-Profile: Amanda Timler

Förderung

  • MGC Pharmaceuticals

Zitieren

APA

Timler, A., Bulsara, C., Bulsara, M., Vickery, A., Jacques, A., & Codde, J. (2023). Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial. Australasian Journal on Ageing, 42(4), 698-709. https://doi.org/10.1111/ajag.13224

Vancouver

Timler A, Bulsara C, Bulsara M, Vickery A, Jacques A, Codde J. Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial. Australasian Journal on Ageing. 2023;42(4):698-709. doi:10.1111/ajag.13224

BibTeX
@article{Timler2023,
  author = {Timler, Amanda and Bulsara, Caroline and Bulsara, Max and Vickery, Alistair and Jacques, Angela and Codde, Jim},
  title = {Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial},
  journal = {Australasian Journal on Ageing},
  year = {2023},
  volume = {42},
  number = {4},
  pages = {698--709},
  doi = {10.1111/ajag.13224}
}
Kostenlos starten →